TScan Therapeutics (TCRX) Net Cash Flow (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Net Cash Flow of -$24.3 million for Q1 2026, up 0.94% year-over-year from -$24.1 million in Q1 2025, and down 42.39% quarter-over-quarter from -$17.1 million in Q4 2025.
TScan Therapeutics (TCRX) Net Cash Flow (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Net Cash Flow for 7 consecutive years, with -$24.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 0.94% year-over-year to -$24.3 million; the TTM figure through Mar 2026 stood at -$26.1 million (down 291.62% YoY), while the FY2025 annual figure was -$26.3 million, down 157.98% from the prior year.
- Net Cash Flow slipped to -$24.3 million in Q1 2026 per TCRX's latest filing, from -$17.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $101.6 million in Q2 2024 and bottomed at -$109.0 million in Q3 2024.
- Historically, Net Cash Flow has averaged -$9.9 million across 5 years, with a median of -$17.3 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 558.42% — and 2024, when it jumped 552.93%.
- TScan Therapeutics' Net Cash Flow stood at -$17.3 million in 2022, then declined by 26.36% to -$21.8 million in 2023, then soared by 308.72% to $45.6 million in 2024, then slumped by 137.52% to -$17.1 million in 2025, then sank by 42.39% to -$24.3 million in 2026.
- Business Quant data shows TCRX's Net Cash Flow at -$24.3 million in Q1 2026, -$17.1 million in Q4 2025, and $112000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -28.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.00 Mn |
| Jun 30, 2026 | -28.00 Mn |
| Mar 31, 2026 | -24.35 Mn |
| Mar 31, 2026 | -24.35 Mn |
| Dec 31, 2025 | -17.10 Mn |
| Dec 31, 2025 | -17.10 Mn |
| Sep 30, 2025 | 112,000.00 |
| Sep 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 15.29 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | -24.58 Mn |
| Mar 31, 2025 | -24.58 Mn |
| Dec 31, 2024 | 45.57 Mn |
| Dec 31, 2024 | 45.57 Mn |
| Sep 30, 2024 | -109.04 Mn |
| Sep 30, 2024 | -109.04 Mn |
| Jun 30, 2024 | 101.65 Mn |
| Jun 30, 2024 | 101.65 Mn |
| Mar 31, 2024 | 7.15 Mn |
| Mar 31, 2024 | 7.15 Mn |